Benitec Biopharma (NASDAQ: BNTC) — Company Overview, News & Financial Data
Benitec Biopharma specializes in gene-silencing technology for chronic diseases, addressing unmet medical needs through innovative therapies.

Benitec Biopharma
Benitec Biopharma (NASDAQ:BNTC) is a dynamic biotechnology firm focused on the development of genetic medicines. Benitec's innovative approach leverages its proprietary gene-silencing technology, called DNA-directed RNA interference (ddRNAi), to create therapies aimed at treating chronic and life-threatening diseases. The company's pipeline includes projects targeting conditions such as hepatitis B, age-related macular degeneration, and oculopharyngeal muscular dystrophy, showcasing its commitment to addressing unmet medical needs through groundbreaking research. With a mission to pioneer the next generation of genetic medicines, Benitec strives to improve patient outcomes and alter the course of disease with its cutting-edge technologies and therapies.
Snapshot
Operations
Products and/or services of Benitec Biopharma
- BB-301 for oculopharyngeal muscular dystrophy, a gene-silencing therapy aiming to reduce the production of toxic proteins causing muscle weakness.
- Gene therapy projects targeting chronic and life-threatening conditions, leveraging DNA-directed RNA interference technology.
- BB-103 for hepatitis B, a treatment designed to disrupt the viral replication process.
- Collaborations with academic and biomedical entities to develop innovative gene therapies for various diseases.
- Research on ddRNAi technology, a proprietary platform for developing treatments targeting genetic disorders.
- Development services for third-party gene therapy products, including custom gene-silencing constructs and licensing of proprietary technologies.
Benitec Biopharma executive team
- Jerel A. BanksExecutive Chairman & CEO
- Megan Joan BostonCFO & Secretary
- Sophie MukadamChief Operating Officer
- Michael GrahamHead of Discovery & Founding Scientist
- Claudia KlothSenior Vice President of Manufacturing
Recent announcements
What Benitec Biopharma (BNTC) has told the market, newest first.
Dividend history
Dividends per share paid by Benitec Biopharma , by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2018 | $0.7650 | — | — | $0.7650 |
Key financials
Reported results for Benitec Biopharma , in AUD.
- Market cap
- 294M
- Revenue (TTM)
- 7K
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -51.2M | -45.5M | |
| 0 | -41.8M | -37.9M | |
| 216K | -22.5M | -21.8M | |
| 75K | -19.1M | -19.6M |